Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vatiquinone by PTC Therapeutics for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes): Likelihood of Approval
Vatiquinone is under clinical development by PTC Therapeutics and currently in Phase III for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis...
Vatiquinone by PTC Therapeutics for Subacute Necrotizing Encephalomyelopathy (Leigh Disease): Likelihood of Approval
Vatiquinone is under clinical development by PTC Therapeutics and currently in Phase III for Subacute Necrotizing Encephalomyelopathy (Leigh Disease). According...
Vatiquinone by PTC Therapeutics for Friedreich Ataxia: Likelihood of Approval
Vatiquinone is under clinical development by PTC Therapeutics and currently in Phase III for Friedreich Ataxia. According to GlobalData, Phase...
Vatiquinone by PTC Therapeutics for Epilepsy: Likelihood of Approval
Vatiquinone is under clinical development by PTC Therapeutics and currently in Phase III for Epilepsy. According to GlobalData, Phase III...